Showing 31-40 of 159 results for "".
Hot Topic: Picture Perfect
https://practicaldermatology.com/topics/practice-management/hot-topic-picture-perfect/19567/Standardizing before and after photos in your practice is a must, explains Todd E. Schlesinger, MD. He sits down with Joel L. Cohen, MD to offer tips on improving the quality of photos from what type of camera to use to standardizing camera settings, the angle of photos, and the backdrop used.Practical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 2
https://practicaldermatology.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-2/32758/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss the differences between psoriasis subtypes, the importance of a specialized therapeutic approach targeting the IL-36 pathway for generalized pustular psoriasis, and the role of neutrophiSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Journal Club: What's New in Pathogenesis and Treatment of Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-whats-new-in-pathogenesis-and-treatment-of-atopic-dermatitis/26247/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Jason E. Hawkes, MD, a dermatologist practicing in the Sacramento area, and a member of the Practical Dermatology Editorial Board, about the latest research on the pathogenesis of and treatment targets for atopic dermatitis (AD).Why Assessing Vitiligo Activity is Critical for Limiting Spread
https://practicaldermatology.com/conferences/maui-derm-2024/why-assessing-vitiligo-activity-is-critical-for-limiting-spread/20248/Chief Medical Editor Neal Bhatia, MD talks with “Mr. Vitiligo Himself,” John E. Harris, MD, PhD about the importance of determining whether vitiligo patients are active or stable in order to “shut off” spreading as soon as possible.Meaningful Approaches to Vitiligo
https://practicaldermatology.com/topics/general-topics/meaningful-approaches-to-vitiligo/18599/As science continues to uncover more about vitiligo and its treatment, dermatologists have more options than ever. But there's still work to be done. In this edition of Ask an Expert, host Adam Friedman, MD talks to John E. Harris, MD, PhD, Director of the Vitiligo Clinic and Research Center at UnivNordlys™: A Foundational Platform For Your Practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/nordlys-a-foundational-platform-for-your-practice/19628/Don’t miss this informative webinar with E. Victor Ross, MD about his experience with the Nordlys system. Nordlys includes 3 foundational technologies: Ellipse IPL, Frax 1550, and Nd:Yag 1064. The benefits of narrowband IPL with dual filters and sub-millisecond pulses will be examined. Dr. Ross willRF Technologies: What should you know?
https://practicaldermatology.com/series/scientifically-speaking/rf-technologies-what-should-you-know/19848/With so many radiofrequency devices now on the market and new ones in development, aesthetic specialists need to know how to select the proper tool for each patient need. E. Victor Ross, MD and Erez Dayan, MD join host Joel L. Cohen, MD to go beyond the marketing jargon to assess the science and cliOn New Therapeutics and Real Sushi
https://practicaldermatology.com/series/the-practical-dermatology-podcast/on-new-therapeutics-and-real-sushi/32849/The latest news and updates, plus E. James Song, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the 2025 outlook for new therapeutics and play "Two Truths and a Lie." Dr. Song says he has been a wrestler, a jazz musician, and a sushi cheDermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent e